CL2016000019A1 - Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. - Google Patents
Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.Info
- Publication number
- CL2016000019A1 CL2016000019A1 CL2016000019A CL2016000019A CL2016000019A1 CL 2016000019 A1 CL2016000019 A1 CL 2016000019A1 CL 2016000019 A CL2016000019 A CL 2016000019A CL 2016000019 A CL2016000019 A CL 2016000019A CL 2016000019 A1 CL2016000019 A1 CL 2016000019A1
- Authority
- CL
- Chile
- Prior art keywords
- hypotension
- depression
- treatment
- pharmaceutical composition
- alzheimer
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 208000001953 Hypotension Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000036543 hypotension Effects 0.000 title abstract 2
- 239000002858 neurotransmitter agent Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 208000019116 sleep disease Diseases 0.000 title abstract 2
- -1 dihydroxyphenyl Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361843549P | 2013-07-08 | 2013-07-08 | |
| US201462010098P | 2014-06-10 | 2014-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016000019A1 true CL2016000019A1 (es) | 2016-11-04 |
Family
ID=52133230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016000019A CL2016000019A1 (es) | 2013-07-08 | 2016-01-07 | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. |
Country Status (16)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY194181A (en) * | 2016-08-30 | 2022-11-17 | Theravance Biopharma R&D Ip Llc | Compound for use in the treatment of neurogenic orthostatic hypotension |
| GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| EP3946329A4 (en) | 2019-03-27 | 2022-11-30 | Curasen Therapeutics, Inc. | BETA ADRENE AGONIST AND METHODS OF USE |
| JP2022529781A (ja) | 2019-04-17 | 2022-06-24 | コンパス パスファインダー リミテッド | サイロシビンによるうつ病及び他の様々な障害の治療 |
| JP7737367B2 (ja) * | 2019-10-25 | 2025-09-10 | キュラセン セラピューティクス インコーポレイテッド | α１Ａ－ＡＲ部分アゴニストを用いて神経障害を治療するための方法 |
| WO2021247963A1 (en) * | 2020-06-05 | 2021-12-09 | Senda Biosciences, Inc. | (s)-alpha-fluoromethyltyrosine as decarboxylase inhibitors for use in the treatment of hypotension |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3360726D1 (en) * | 1982-01-14 | 1985-10-17 | Sumitomo Chemical Co | Process for producing threo-3-(3,4-dihydroxyphenyl)serine |
| CA1223602A (en) | 1983-05-25 | 1987-06-30 | Naohito Ohashi | Process for producing 3-(3,4-dihydroxyphenyl) serine |
| JP3764179B2 (ja) | 1994-07-05 | 2006-04-05 | 克寛 西野 | 運動・意識または言語障害の機能改善剤 |
| DE19619510A1 (de) | 1995-05-18 | 1996-11-21 | Sumitomo Chemical Co | Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin |
| JP3489319B2 (ja) | 1996-03-12 | 2004-01-19 | 住友化学工業株式会社 | カルボン酸誘導体、その製造法および用途 |
| JPH115738A (ja) | 1997-06-15 | 1999-01-12 | Katsuhiro Nishino | 脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤 |
| US6376531B1 (en) * | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| DE10261807A1 (de) * | 2002-12-19 | 2004-07-01 | Turicum Drug Development Ag | Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel |
| WO2005084330A2 (en) | 2004-03-02 | 2005-09-15 | Synergia Pharma, Inc. | Compositions and methods for treating nasal congestion |
| USRE46555E1 (en) * | 2006-02-17 | 2017-09-19 | Teva Pharmaceuticals International Gmbh | Deuterated catecholamine derivatives and medicaments comprising said compounds |
| US8008285B2 (en) | 2007-03-09 | 2011-08-30 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia |
| ES2395868T3 (es) | 2007-03-12 | 2013-02-15 | Chelsea Therapeutics, Inc. | Droxidopa y composición farmacéutica de la misma para el tratamiento de la hipotensión mediada neuralmente |
| NZ581707A (en) | 2007-05-07 | 2011-05-27 | Chelsea Therapeutics Inc | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
| US7745665B2 (en) | 2007-06-04 | 2010-06-29 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines |
| WO2010054286A2 (en) * | 2008-11-10 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Substituted hydroxyphenylamine compounds |
| US9072730B2 (en) | 2009-05-14 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease |
| JPWO2011001976A1 (ja) | 2009-07-01 | 2012-12-13 | 大日本住友製薬株式会社 | スレオ−３−（３，４−ジヒドロキシフェニル）−ｌ−セリンの製造法 |
| JP5880913B2 (ja) | 2011-05-17 | 2016-03-09 | 三郎 佐古田 | パーキンソン病の体幹症状（姿勢反射異常）の治療剤 |
| US20130253061A1 (en) | 2012-03-20 | 2013-09-26 | Chelsea Therapeutics, Inc. | Method of droxidopa synthesis |
-
2014
- 2014-07-08 SG SG10201800166UA patent/SG10201800166UA/en unknown
- 2014-07-08 KR KR1020167003133A patent/KR20160041912A/ko not_active Withdrawn
- 2014-07-08 US US14/325,988 patent/US20150011630A1/en not_active Abandoned
- 2014-07-08 AU AU2014287418A patent/AU2014287418A1/en not_active Abandoned
- 2014-07-08 MX MX2016000219A patent/MX384131B/es unknown
- 2014-07-08 EA EA201600093A patent/EA201600093A1/ru unknown
- 2014-07-08 CA CA2917159A patent/CA2917159C/en active Active
- 2014-07-08 PE PE2016000010A patent/PE20160556A1/es unknown
- 2014-07-08 SG SG11201510764QA patent/SG11201510764QA/en unknown
- 2014-07-08 HK HK16109787.0A patent/HK1221713A1/zh unknown
- 2014-07-08 WO PCT/US2014/045731 patent/WO2015006315A1/en not_active Ceased
- 2014-07-08 EP EP19188210.9A patent/EP3611159B1/en active Active
- 2014-07-08 CN CN201480042918.0A patent/CN105473545B/zh not_active Expired - Fee Related
- 2014-07-08 EP EP14822407.4A patent/EP3019467A4/en not_active Withdrawn
- 2014-07-08 JP JP2016525422A patent/JP6567515B2/ja not_active Expired - Fee Related
- 2014-07-08 BR BR112016000338A patent/BR112016000338A8/pt not_active Application Discontinuation
-
2016
- 2016-01-05 IL IL243488A patent/IL243488A0/en unknown
- 2016-01-07 CL CL2016000019A patent/CL2016000019A1/es unknown
-
2017
- 2017-07-21 US US15/656,035 patent/US20170319694A1/en not_active Abandoned
-
2018
- 2018-06-06 US US16/000,965 patent/US20180280511A1/en not_active Abandoned
- 2018-10-26 AU AU2018253594A patent/AU2018253594A1/en not_active Abandoned
-
2019
- 2019-05-21 IL IL266767A patent/IL266767A/en unknown
- 2019-08-01 US US16/529,187 patent/US20190374642A1/en not_active Abandoned
-
2021
- 2021-08-11 US US17/399,708 patent/US20220072131A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220072131A1 (en) | 2022-03-10 |
| EA201600093A1 (ru) | 2016-08-31 |
| CA2917159C (en) | 2022-08-23 |
| US20150011630A1 (en) | 2015-01-08 |
| CN105473545B (zh) | 2017-08-04 |
| MX2016000219A (es) | 2016-05-31 |
| HK1216747A1 (zh) | 2016-12-02 |
| JP2016529228A (ja) | 2016-09-23 |
| CN105473545A (zh) | 2016-04-06 |
| KR20160041912A (ko) | 2016-04-18 |
| EP3611159B1 (en) | 2023-01-25 |
| EP3019467A4 (en) | 2017-03-15 |
| EP3019467A1 (en) | 2016-05-18 |
| US20180280511A1 (en) | 2018-10-04 |
| US20170319694A1 (en) | 2017-11-09 |
| HK1221713A1 (zh) | 2017-06-09 |
| AU2014287418A1 (en) | 2016-01-28 |
| SG10201800166UA (en) | 2018-02-27 |
| IL266767A (en) | 2019-07-31 |
| US20190374642A1 (en) | 2019-12-12 |
| WO2015006315A1 (en) | 2015-01-15 |
| JP6567515B2 (ja) | 2019-08-28 |
| AU2018253594A1 (en) | 2018-11-22 |
| BR112016000338A2 (pt) | 2017-08-22 |
| MX384131B (es) | 2025-03-14 |
| SG11201510764QA (en) | 2016-01-28 |
| BR112016000338A8 (pt) | 2020-01-07 |
| CA2917159A1 (en) | 2015-01-15 |
| EP3611159A1 (en) | 2020-02-19 |
| PE20160556A1 (es) | 2016-06-11 |
| IL243488A0 (en) | 2016-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
| MX2018001721A (es) | 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer. | |
| CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
| CL2016002812A1 (es) | Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación. | |
| CL2016002573A1 (es) | Compuesto de ciclopropanamina y sus usos. | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| MX2021003840A (es) | Profarmacos de carbidopa y l-dopa y metodos de uso. | |
| CR20160237A (es) | Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| CU20170172A7 (es) | 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
| CL2015002855A1 (es) | Derivados de oxopiridina sustituida. | |
| UY36445A (es) | Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi) | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| UY36452A (es) | Novedosos compuestos moduladores de fxr (nr1h4) | |
| NI201500140A (es) | Compuestos y composiciones terapéuticos | |
| CL2015003690A1 (es) | Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington. | |
| CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
| CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
| CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. |